GLP‑1s and sex lives
New coverage is flagging that GLP‑1 drugs could affect sexual health and libido — researchers and reporters say these medications influence hormones and physiology beyond blood sugar and appetite, so sex‑drive changes are showing up in patient reports. That’s a practical side effect many users and clinicians are only now tracking systematically. (self.com)
These drugs were built to quiet hunger, but some users are now saying they also quieted something else: sexual desire. The new reporting is landing because glucagon-like peptide-1 drugs are now common enough that doctors are hearing the same story from multiple directions at once. (self.com) Glucagon-like peptide-1 is a gut hormone your body already makes after you eat. Drugs like semaglutide copy that signal and bind to receptors across the brain and body, which is why they affect more than blood sugar alone. (nature.com) One reason libido may shift is that these drugs act on the same reward circuits that help drive cravings. A 2026 review says glucagon-like peptide-1 receptor agonists may influence reward-related and sexual behaviors, which gives researchers a plausible brain-based mechanism to study. (pubmed.ncbi.nlm.nih.gov) Animal studies are one clue, not a verdict. In rodents, activating these pathways reduced sexual interaction behaviors and sexual motivation in several brain regions, while human evidence stayed mixed and much thinner. (pubmed.ncbi.nlm.nih.gov) That mixed picture is already showing up in real people. A 2025 Kinsey Institute survey of 2,000 single U.S. adults found that about 52% of glucagon-like peptide-1 users said the drugs affected their sex lives, with 18% reporting higher desire and 16% reporting lower desire. (news.iu.edu) The same survey found body image moving in both directions too. Sixteen percent said they felt more comfortable naked, while 14% said they felt less comfortable, which helps explain why one person can feel newly confident and another can feel less interested in sex on the same class of drug. (news.iu.edu) There is also a very ordinary physical explanation that has nothing to do with romance or psychology. Wegovy and Ozempic list nausea, vomiting, diarrhea, constipation, stomach pain, and dehydration among important side effects, and people who feel sick, dry, or exhausted often do not feel especially sexual. (wegovy.com) (ozempic.com) Some researchers are looking specifically at men because erectile function is easier to measure than desire. A 2026 narrative review says pharmacovigilance databases have logged reports of erectile dysfunction, decreased libido, and orgasmic dysfunction, but those signal-detection systems cannot prove the drug caused the problem. (pubmed.ncbi.nlm.nih.gov) The cleanest human experiment so far did not find a simple direct hit. In a randomized crossover trial, four weeks of dulaglutide in healthy lean men showed no effect on sexual desire, reproductive hormones, or semen parameters. (thelancet.com) So the story in April 2026 is not “glucagon-like peptide-1 drugs kill libido.” The story is that these medicines change appetite, reward, body image, weight, hormones, stomach function, and energy level all at once, and researchers are only now trying to sort out which of those changes improve sex, which hurt it, and for whom. (self.com) (pubmed.ncbi.nlm.nih.gov)
